CA2175282A1 - Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer - Google Patents

Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer

Info

Publication number
CA2175282A1
CA2175282A1 CA002175282A CA2175282A CA2175282A1 CA 2175282 A1 CA2175282 A1 CA 2175282A1 CA 002175282 A CA002175282 A CA 002175282A CA 2175282 A CA2175282 A CA 2175282A CA 2175282 A1 CA2175282 A1 CA 2175282A1
Authority
CA
Canada
Prior art keywords
hyaluronic acid
sodium hyaluronate
dosage
cancer
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002175282A
Other languages
English (en)
Inventor
Rudolf Edgar Falk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyal Pharmaceutical Corp
Original Assignee
Hyal Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp
Priority to CA002175282A priority Critical patent/CA2175282A1/fr
Priority to ZA9703622A priority patent/ZA973622B/xx
Priority to AU25644/97A priority patent/AU2564497A/en
Priority to PCT/CA1997/000283 priority patent/WO1997040841A1/fr
Priority to ARP970101754A priority patent/AR006892A1/es
Publication of CA2175282A1 publication Critical patent/CA2175282A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA002175282A 1996-04-29 1996-04-29 Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer Abandoned CA2175282A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002175282A CA2175282A1 (fr) 1996-04-29 1996-04-29 Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
ZA9703622A ZA973622B (en) 1996-04-29 1997-04-25 Use of forms of hyaluronic acid (HA) for the treatment of cancer.
AU25644/97A AU2564497A (en) 1996-04-29 1997-04-28 Use of formes f hyaluronic acid (ha) for the treatment of cancer
PCT/CA1997/000283 WO1997040841A1 (fr) 1996-04-29 1997-04-28 Emploi de formes d'acide hyaluronique (ha) pour therapie anticancereuse
ARP970101754A AR006892A1 (es) 1996-04-29 1997-04-29 Uso de formas del acido hialuronico (ha) para el tratamiento del cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002175282A CA2175282A1 (fr) 1996-04-29 1996-04-29 Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA2175282A1 true CA2175282A1 (fr) 1997-10-30

Family

ID=4158095

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002175282A Abandoned CA2175282A1 (fr) 1996-04-29 1996-04-29 Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer

Country Status (5)

Country Link
AR (1) AR006892A1 (fr)
AU (1) AU2564497A (fr)
CA (1) CA2175282A1 (fr)
WO (1) WO1997040841A1 (fr)
ZA (1) ZA973622B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
NZ512676A (en) 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
ATE361082T1 (de) 1999-02-01 2007-05-15 Dermal Res Lab Inc Pharmazeutische zusammensetzung aus komplexen kohlenhydraten deren anwendung
WO2000054762A2 (fr) * 1999-03-15 2000-09-21 Trustees Of Boston University Inhibition d'une angiogenese
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
AU760404B2 (en) * 2000-07-14 2003-05-15 Alchemia Oncology Pty Limited Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AU8136801A (en) * 2000-07-31 2002-02-13 Dermal Res Lab Inc Methods of preventing or treating diseases and conditions using complex carbohydrates
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
CN1578677A (zh) * 2001-08-27 2005-02-09 美迪泰克研究有限公司 改良的治疗方案
AU2002325635C1 (en) * 2001-08-27 2008-09-25 Alchemia Oncology Pty Limited Improved therapeutic protocols
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
CN103784960A (zh) 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
US8623354B2 (en) 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US9375447B2 (en) * 2013-03-14 2016-06-28 National Cheng Kung University Modified hyaluronan and uses thereof in cancer treatment
CN105311051A (zh) 2014-05-26 2016-02-10 陈松源 具有增加抗肿瘤药物疗效的载体溶媒、制备方法及其给药途径

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US5464942A (en) * 1990-07-24 1995-11-07 Seikagaku Kogyo Kabushiki Kaisha Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same
CA2122519C (fr) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Traitement du cancer et prevention des metastases
AU6362594A (en) * 1993-03-10 1994-09-26 Miles Inc. Hyaluronic acid used as a cancer treatment

Also Published As

Publication number Publication date
WO1997040841A1 (fr) 1997-11-06
AU2564497A (en) 1997-11-19
ZA973622B (en) 1997-11-25
AR006892A1 (es) 1999-09-29

Similar Documents

Publication Publication Date Title
JP3256761B2 (ja) 症状及び疾病の治療
US5614506A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
CA2122519C (fr) Traitement du cancer et prevention des metastases
CA2175282A1 (fr) Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
EP0873128A1 (fr) Administration orale de quantites efficaces de formes de l'acide hyaluronique
EP0874624B1 (fr) Ligands des recepteurs a l'acide hyaluronique et leur utilisation dans le traitement des tumeurs et de la restenose
CA2164260C (fr) Methode de ciblage pour medicaments et agents therapeutiques
CA2167044C (fr) Administration par voie orale de quantites efficaces de certaines formes d'acide hyaluronique
WO1998052613A2 (fr) Methode d'administration d'agent therapeutique utilisant des formes appropriees d'acide hyaluronique et des combinaisons avec l'electroporation
AU6173599A (en) Treatment of conditions and disease
CA2131130A1 (fr) Modulation de l'activite cellulaire
CZ288292B6 (en) Compound therapeutic preparations intended for treatment of diseases or states of tissues comprising insufficiently perfused tissues and pathological tissues of human being
CA2166154A1 (fr) Agents liants et utilisation correspondante
CA2193921A1 (fr) Administration orale de quantites efficaces de formes d'acide hyaluronique repondant a diverses normes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead